西罗莫司片是医保用药吗？

(Leipaming) Is it a medical insurance drug? Medical insurance drugs refer to drugs that are necessary to ensure the clinical treatment of employees and are included in the scope of basic medical insurance benefits. They are divided into Category A and Category B. Since sirolimus tablets (rapamin) are not found in the "Basic Medical Insurance Drug Catalog", sirolimus tablets (rapamin) are not yet medical insurance drugs.

Sirolimus tablets (rapamin) are suitable for patients undergoing kidney transplantation. It is recommended to be used in combination with cyclosporine and corticosteroids to prevent organ rejection. Sirolimus tablets (rapamin) inhibit the activation and proliferation of T lymphocytes stimulated by antigens and cytokines (interleukins IL-2, IL-4 and IL-15). It also inhibits the production of antibodies. In cells, sirolimus (rapamin) binds to the immunophilin, FK-binding protein-12 (FKBP-12), to generate the FKBP-12 immunosuppressive complex. This complex binds to the mammalian Siros BA molecule (mTOR, a key regulatory kinase) and inhibits its activity, thereby inhibiting the progression from G1 to S phase in the cell cycle.

The safety and efficacy of sirolimus tablets (rapamin) in children under 13 years of age have not been determined. If used in children under 13 years of age, it is recommended to monitor the whole blood trough concentration of sirolimus tablets (rapamin).

At the same time, this type of compound also has the potential to treat stroke, neurodegenerative diseases, Parkinson's syndrome, Alzheimer's disease, etc. Harrison et al. reported in Nature magazine in July 2009 that rapamycin can extend the lifespan of aging mammalian mice, which immediately aroused widespread attention and high interest among scientists from all over the world. The American "Science" magazine selected this research result as one of the top ten scientific advances of the year. Because sirolimus tablets (rapamin) have low nephrotoxicity, they can maintain long-term stability of renal function, and they can also reduce the incidence of tumors in transplant patients while suppressing immunity. It is generally believed that rapamycin binds to FKBP12, and the RAPA-FKBP12 complex binds to the mammalian target of rapamycin (mTOR), inhibiting the proliferation of T lymphocytes and B lymphocytes caused by various stimuli, causing cells to stay in the late G1 phase of the cell cycle, and preventing these cells from entering the S phase.

The above is the medical insurance situation of (Leipaming) provided to you by our Medical Companion Travel Overseas Medical Consulting Service Company.

Recommended related hot articles: /newsDetail/76778.html